What clinical and pathological features do you consider when deciding which androgen receptor targeted agent to combine with ADT for a patient with newly diagnosed castrate sensitive metastatic prostate cancer?  

Regarding which novel hormonal agent I use with ADT, there are no specific pathologic features which suggest that any one agent is better than any others as far as I know, so I do not consider that in the decision. The primary reasons why I choose an agent are based on adverse events and side effect...

There are many clinical and pathologic considerations theoretically that could impact treatment decisions in men with mHSPC. Key are disease volume and de novo vs relapsed disease, but also critical are patient comorbidity and preference, costs and financial toxicity, drug drug interactions, contrai...